International Journal of Molecular Sciences Impact Factor

The 4.9 JIF means that IJMS papers are cited at a moderate rate within the two-year JCR window. That's a respectable number on its own. The five-year JIF (5.7) running above the two-year number shows some long-tail citation accrual.

But the volume context is everything here. IJMS publishes more than 10,000 articles per year and has over 13,500 citable items. That makes it one of the largest journals in all of science. The Q1 ranking reflects the large denominator in the Biochemistry & Molecular Biology category (319 journals), where even a moderate JIF puts you in the top quartile.

What this means practically:

Acceptance rates are high. MDPI's editorial model is volume-driven and open-access fee-supported. The acceptance rate is substantially higher than traditional Q1 biochemistry journals. Getting published here is not difficult for technically sound work.

Special issues dominate the output. A large share of IJMS publications come through special issues, where guest editors solicit papers on specific topics. The review standards for special-issue papers can vary significantly from the journal's regular submissions.

The prestige signal is debated. In some communities and geographies, IJMS is perfectly acceptable. In others, particularly in competitive academic markets in North America and Europe, an IJMS publication carries less weight than a traditional Q1 journal at a similar or even lower JIF. You should be realistic about how your specific audience reads this journal name.

• how hiring committees in your field read an IJMS publication
• whether a traditional Q2 journal with lower JIF might carry more weight on your CV
• how discoverable your paper will be within 10,000+ annual articles
• how variable review quality is across regular and special-issue submissions
• whether the open-access fee ($2,700+) is the best use of publication funds

IJMS peaked in 2021 at ~6.2 during the pandemic-era citation surge and has since declined. This pattern is common across MDPI journals and reflects both the broader citation normalization and increasing scrutiny of high-volume open-access models. The current 4.9 is the operative number for planning.

MDPI publishes through an open-access, author-pays model with fast turnaround times (often 2-4 weeks from submission to first decision). The editorial model uses academic editors and external reviewers, but the sheer volume means review depth can be uneven.

The model works well for:

• authors who need a quick, indexed publication
• researchers in regions where IJMS is well-regarded
• incremental contributions that are technically sound but not prestige plays

The model works less well for:

• authors in competitive tenure-track markets where journal name matters
• papers that deserve deeper engagement from reviewers
• work that would benefit from the editorial curation of a more selective venue

In our pre-submission review work with manuscripts targeting International Journal of Molecular Sciences, three patterns generate the most consistent desk rejections and quality concerns.

Special issue submission without verifying editorial oversight quality. IJMS publishes approximately 10,000 articles per year, the majority through special issues managed by external Guest Editors. MDPI's author guidelines acknowledge the special issue structure, and the journal's editorial model depends on Guest Editors to screen submissions in their topic area. The most common quality issue: authors submit to a special issue based on its topical relevance without verifying that the Guest Editor has active research expertise in the topic and a track record of rigorous review management. Special issues with Guest Editors whose publication record shows no work in the special issue's topic area, or with Guest Editors who have unusually high acceptance rates, are a known quality risk. Verifying the Guest Editor's credentials before submission takes two minutes and substantially changes the review quality you can expect.

Clinical or translational medicine paper submitted to a molecular sciences journal. IJMS publishes research "providing insights into molecules" and covers biochemistry, molecular biology, and related molecular science. Clinical studies, epidemiological research, and patient cohort studies are outside the journal's scope, even when they mention molecular endpoints. Papers reporting clinical outcomes, patient-level statistics, or healthcare system data face desk rejection for scope mismatch. The journal can accommodate molecular mechanism papers with in vitro or in vivo model data; it is not the right venue for clinical research regardless of whether a molecular pathway is mentioned in the abstract.

Computational molecular study without experimental validation in the same paper. IJMS is an experimental molecular science journal. Computational papers (molecular docking, DFT, QSAR, MD simulation) that do not include any experimental validation of the key computational findings are regularly rejected. The standard expectation: if the paper predicts protein-ligand binding affinity computationally, at least basic in vitro binding or activity data should accompany the prediction. Papers that are purely in silico without experimental grounding in the same manuscript should target dedicated computational chemistry or bioinformatics journals where pure computational work is the norm.

A IJMS scope and validation check can assess whether the experimental validation and paper type meet IJMS's molecular science scope before submission.

Submit if:

• you want a credible, well-indexed molecular biology venue
• the work is solid and publishable even if it's not a prestige target
• speed and open-access availability matter more than brand signaling
• the paper fits one of IJMS's active special issues

Think twice if:

• the paper could credibly land in a stronger specialty journal
• you need the journal name to carry real weight in hiring or grant review
• a more targeted journal would give the work better readership and engagement
• the open-access fee is significant relative to your funding

The headline IF of 4.9 doesn't tell the full story. Here's the complete JCR profile:

The number that deserves more attention is the JCI of 0.71. That indicator normalizes citations by field and document type, a JCI below 1.0 means IJMS papers are, on average, cited less than you'd expect for their category. The Q1 ranking looks strong, but it's partly an artifact of having 319 journals in the denominator. In a category that large, even a middling IF lands you in the top quartile. The 3.5-year cited half-life also suggests that IJMS papers don't accumulate citations the way papers in more selective journals do, they get read early, cited modestly, and then fade.

Let's put that 10,013 articles/year number in context:

IJMS publishes 30-90x the volume of its Q1 peers. That's not a rounding difference, it's a fundamentally different publishing model. The consequences are real: individual papers have lower per-article visibility, editors can't give each submission deep attention, and the journal's citation metrics are driven more by volume than by any single paper's influence. Hiring committees and grant reviewers in competitive markets often know this. They'll see the Q1 label and then check the journal name, and the MDPI brand carries a different weight than Molecular Cell or EMBO Journal. This isn't about whether IJMS is "legitimate", it is. It's about whether publishing there sends the signal you actually want to send.

Not every paper needs to land in a selective journal. Here's an honest breakdown by career stage and paper type:

If you're at a stage where every line on your CV gets scrutinized (tenure cases, R1 faculty searches, competitive grant panels) an IJMS paper won't hurt you, but it won't help as much as the Q1 label suggests. The people reading your file know the difference between Q1-by-category-size and Q1-by-selectivity. On the other hand, if you need a fast, indexed, technically credible publication and the career stakes aren't riding on this particular paper, IJMS does what it says. The key is matching the journal to the paper's actual role in your career, not to its JCR quartile.

If you're unsure whether IJMS is the right target or if a more selective journal is realistic for your manuscript, a IJMS fit check can help you make that call before you commit.

Here's something many authors don't realize: a large share of IJMS publications come through special issues, not regular submissions. Guest editors, typically mid-career or senior researchers, propose a topic, MDPI approves it, and the guest editor recruits papers. This model drives IJMS's volume and shapes the experience authors actually have.

The special issue model isn't inherently bad. It can connect you with a themed collection that improves discoverability. But you should know what you're getting into. Some guest editors run tight ships with genuine peer review. Others accept most submissions because MDPI's model incentivizes volume. Before accepting a special issue invitation, check the guest editor's own publication record and whether the topic is specific enough to attract a real audience. A vague special issue title ("Recent Advances in Molecular Biology") is a red flag for low curation.